



EASL

INTERNATIONAL
LIVER
FOUNDATION

NAFLD POLICY REVIEW

ELPA: "Preventing the NAFLD-NASH Epidemic: The Patient Perspective"

Brussels, 8 Jan 2019

Prof. Jeffrey V Lazarus, EILF Vice-chairman of the board

On behalf of the EILF NAFLD Policy Review Collaborators

Co-PIs: Jeffrey V. Lazarus, Quentin Anstee and Helena Cortez-Pinto

The EASL International Liver Foundation

MISSION

The EASL International Liver Foundation is a global non-profit organization, established by the European Association for the Study of the Liver (EASL), committed to increasing the quality of life and reducing premature mortality for the greatest number of people by improving liver health. 4 pillars guide our action:

4 PROGRAMME PILLARS



THE BOARD OF DIRECTORS



Massimo Colombo
MD, Professor of Medicine, Head of Traslational Liver Research, IRCCS, Humanitas, Milan, Italy, Chairman, EASL International Liver Foundation, Geneva, Switzerland



Christian Bréchet
MD Ph.D, is retired President, Institut Pasteur, Paris, France



Tom H. Karlsen
MD, PhD, Full Professor of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway, Secretary General of EASL, Geneva, Switzerland



Jordi Bruix
is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain



Andrea Sironi
is Professor of Banking and Finance at Bocconi University in Milan. He is Chairman of Borsa Italiana SpA and, member of the Board of Directors of the London Stock Exchange Group.



Benoit Merkt
Dr. iur., Attorney at Law, MJur has been a partner of the Swiss law firm Lenz & Staehelin since 2006. He is co-head of Lenz & Staehelin competition law and non-profit/philanthropy practices.



Mark Thursz
is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and lead clinician for hepatology at St Mary's Hospital, London.



Stefan Wiktor
is Professor of Medicine and Public Health at the University of Washington in Seattle, U.S. He was the Team Lead of the World Health Organization's Global Hepatitis Programme in Geneva, Switzerland.



Philip N. Newsome
Director of the Centre for Liver Research & Professor of Experimental Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham, Vice-Secretary General of EASL, Geneva Switzerland



Jeffrey V. Lazarus
PhD, MEd, MA, Associate researcher at the Barcelona Institute of Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Vice-Chairman EASL International Liver Foundation.



Manal El Sayed
Professor of Paediatrics at Ain Shams University, Cairo, Egypt. Since 2011 Vice Chair of the WHO's Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt and supervisor (oversight) of the Egyptian national program for control of viral hepatitis at Ministry of Health.

NAFLD Policy Review

Goal

To encourage key stakeholders in Europe to rally around the fight against NAFLD/NASH.

Objectives

Raise awareness about NAFLD/NASH across Europe;

- Evaluate the extent to which European Union member countries have key policies and guidelines in place to address NAFLD/NASH;
- Identify the gaps and opportunities for improvement in NAFLD/NASH policies and guidelines;
- Mobilize follow-up action.



Method

Survey Instrument

- 24-item English-language survey;
 - Items were a mix of multiple choice and open-ended questions.
- Items were presented under 6 categories: (i) policies/guidelines; (ii) awareness and continues medical education; (iii) monitoring and data; (iv) prevention, testing and diagnosis; (v) clinical assessment; and (vi) treatment.

Data Collection

- Survey participants were recruited through a purposive sampling process.
- A NAFLD expert was selected from each study country.
- Each survey lead was tasked with completing 1 single survey for their country and received written guidance recommending that they create an informal *country specific team* of 5-6 members.

Phase 1

Data collection: 19th February – 26th March 2018

Phase 1 Countries and Leads:



France

Vlad Ratziu



Germany

Frank Tacke



Italy

Giulio Marchesini



Portugal

Helena Cortez-Pinto



Slovenia

Marko Korenjak & Katja Novak



Spain

Manuel Romero-Gomez



Sweden

Mattias Ekstedt




UK


Quentin Anstee

Preliminary Results: Policies and Guidelines



Does your country have any written national NAFLD/NASH strategy/action plan?






Is NAFLD/NASH specifically accounted for in other relevant disease strategy/action plans ?



Countries with Strategy/Action Plan




NAFLD/NASH mentioned



Does your country have national clinical guidelines for the prevention, diagnosis and/or treatment of NAFLD/NASH?

- Overall, 50% of countries have national clinical guidelines.
- Although Italy has guidelines endorsed by the national society, they have limited impact at regional or national level.








■ Yes ■ No ■ In Development

Is NAFLD/NASH specifically accounted for in other relevant national/regional disease clinical guidelines?


Countries with clinical guidelines

NAFLD/NASH mentioned



Preliminary Results: Awareness

Do government funded awareness campaigns (in non-hospital/clinic settings) on healthy eating, healthy foods, physical activity, soft drink consumption etc, include any specific mention of any aspect of "liver health"?



Preliminary Results: CME


Do any hepatologic scientific/medical societies have accredited continuing education programmes on NAFLD/NASH at a national level in your country?



Preliminary Results: Monitoring and Data


Does your country have any *national* (not cohort or sub-national) disease registries that include NAFLD/NASH?

Portugal and Spain, the only countries to report yes (for secondary care only).




Does your country have any regional or national NAFLD/NASH cohorts?

Half of countries surveyed report having regional or national NAFLD/NASH cohorts and Italy (Sicily) and Portugal report cohorts to be in development.



Has there been an analysis of the burden of NASH/NAFLD and the cost on its healthcare system / society?



Preliminary Results: Prevention, Testing and Diagnosis

Do regional/national policy/guidelines specifically recommend screening of NAFLD/NASH in patients with related disease/conditions?

Obesity



Diabetes



Harmful Alcohol Use



Dyslipidaemia











Hypertension




Cardiovascular Disease

NO Countries









In your country, which healthcare provider is typically responsible for the care of NAFLD/NASH patients following diagnosis?

	Gastroenterology	Internal Medicine	Hepatology	Primary Care	Multidisciplinary team	Diabetologist	Nutritionist	Endocrinologist
	X		X					
	X	X	X	X		X	X	
	X	X	X		X			
	X	X	X	X	X			
	X		X					
	X		X					
	X			X	X			
	X		X	X	X			

Do national policy/guidelines outline algorithms for follow-up and specialist referral in primary care centres for patients diagnosed with NAFLD/NASH?



According to clinical management guidelines, is HCC systematically assessed upon NAFLD/NASH diagnosis and follow-up?

	Diagnosis	Follow up
	Yes	Yes
	Yes	Yes
	Yes - Position Paper	No
	No	No
	No	No
	No National Guidelines	No National Guidelines
	No National Guidelines	No National Guidelines
	No National Guidelines	No National Guidelines

Preliminary Results: Treatment

Are structured lifestyle programmes aimed at NAFLD/NASH available?



- Germany and the UK are the only countries to report structured lifestyle programs aimed at NAFLD/NASH.
- However, neither are implemented at a national level. Instead, programmes are only being run in certain local, specialised centres.

Next Steps

- Expansion to remaining EU-28 countries currently underway (Launch Q1 2019)
- Anticipated expansion to regions beyond EU-28 (2020)
- Closed-door stakeholder event (Vienna, ILC2019)
- Policy event at the EASL NASH Summit (Sept 2019)
- To build a coalition to address NAFLD/NASH at the global level (ongoing)



Acknowledgements

Co-PIs

Jeffrey V. Lazarus
Quentin Anstee
Helena Cortez-Pinto

Study Group

Laurent Castera
Massimo Colombo
Gianluigi Condorelli
Giovanni Fattore
Loreta Kondili
Marko Korenjak
Giulio Marchesini
Vlad Ratziu
Maria Reig
Frank Tacke
Valerie Vilgrain

Country Leads

Mattias Ekstedt
Marko Korenjak
Giulio Marchesini
Katja Novak
Vlad Ratziu
Manuel Romero-Gomez
Frank Tacke

Country Team Members

SPAIN

Javier Crespo
Juan Turnes
Carmelo Garcia- Monzon
Eva Bench

GERMANY

Ingo van Thiel

ITALY

Salvatore Petta
Giovanni Targher
Antonio Gasbarrini
Roberto Vettor
Ivan Gardini

UK

Guru Aithal
Phil Newsome
Nimatha de Alwis

PORTUGAL

Cristina Ribeiro
Emilia Rodrigues
Rui Tato Marinho

This initiative has been funded through an independent grant to EASL International Liver Foundation by: Gilead Sciences Europe Ltd, Allergan Pharmaceuticals, Pfizer Inc., Bristol-Myers Squibb and Resoundant, Inc..

Contact: Jeffrey.Lazarus@ISGlobal.org